Tubulis
Matthew Norkunas, M.D. currently serves as CFO and President of Tubulis, Inc since January 2025 and as a Board Member and Audit Chair at Obsidian Therapeutics since April 2023. Previously, Matthew Norkunas held the position of Chief Financial Officer at Generation Bio from July 2020 to January 2025 and served as Chief Financial Officer and Head of Corporate & Business Development at SomaLogic from January 2016 to June 2020. Earlier in the career, Matthew Norkunas worked as a Senior Equity Analyst at Marsico Capital Management, an Attending Anesthesiologist at Maimonides Medical Center, and an Anesthesiology Attending at Anesthesia Associates of Savannah. Matthew Norkunas completed an MBA in Finance at Columbia Business School, a residency in Anesthesia at the Icahn School of Medicine at Mount Sinai, and earned a Doctor of Medicine from the University of Maryland School of Medicine. Additionally, Matthew Norkunas holds a Bachelor of Arts in Biology from St. Mary's College of Maryland.
This person is not in any teams
This person is not in any offices
Tubulis
2 followers
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Their goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. They will advance a range of conjugates, unlimited by indication, using their own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.